Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013

Abstract

Citation style for this article:Arnaud I, Maugat S, Jarlier V, Astagneau P. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009. Euro Surveill. 201520(36) E xtended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are a major focus of multidrug-resistant organisms (MRO) surveillance programmes in France. To describe the temporal and geographical trends of these pathogens, we conducted an epidemiological study based on data extracted from the nationwide MRO surveillance network from 2009 to 2013. During this time, the incidence of ESBL-E infections in French hospitals increased by 73%, from 0.35 to 0.60 per 1,000 patient days (PD) (p < 0.001) and ESBL-E bacteraemia by 77%, from 0.03 to 0.05 per 1,000 PD (p < 0.001). The incidence of ESBL-E infections was higher in intensive-care units (1.62 to 2.44 per 1,000 PD (p < 0.001)) than in recovery and long-term care facilities (0.20 to 0.31 per 1,000 PD (p < 0.001)). Escherichia coli was the most frequent extended-spectrum betalactamase-producing (ESBL) pathogen, representing 59% (26,238/44,425) of all ESBL isolates, followed by Klebsiella pneumoniae (20%; 8,856/44,425) in 2013. The most frequent infection was urinary tract infection, for all species. The incidence of ESBL-E varied by region but showed an upward trend overall. Reinforcement of control measures for halting the spread of such MRO is crucial.

Genomic interrogation of the burden and transmission of multidrug-resistant pathogens within and across hospital networks

“…ESBL-Ec was most common, with infection or colonization affecting at least 1.5 in every 1000 patients, higher than some other population-based estimates (e.g. 0.42 and 0.47 per 1000 patient-days in Canada 2009 and France 2013 [31, 32]). Similarly, the burden of MRSA in the study was relatively high, although still much lower than some estimates from other countries (e.g.…”

Nosocomial infection and its molecular mechanisms of antibiotic resistance

“…Other members of ESBLs are rare and have been discovered predominantly in P. aeruginosa and in some small areas: PER-1 was found in France, Italy, and Turkey; VEB family was found Southeast Asia; and GES family and IBC-2 were found in South Africa, France, and Greece (33). A part of these ESBLs were discovered in Enterobacteriaceae as well, but other rare ESBLs, such as BES-1, IBC-1, SFO-1, and TLA-1, have been discovered only in Enterobacteriaceae (34).…”

Incidencia de bacterias multi-resistentes en unidades de cuidados intensivos de hospitales chilenos

“…La gran mayoría de los estudios reportan porcentaje de resistencia frente a distintos antimicrobianos en los aislados de los laboratorios. Estudios de incidencia con metodología similar al nuestro se han realizado, pero en general enfocados en una bacteria multi-resistente en particular o una patología puntual y además, considerando a todos los pacientes hospitalizados, sin separar los datos de pacientes críticos, lo que baja considerablemente la incidencia y lo hace poco comparable a nuestros resultados [8][9][10] . Por otra parte, la mayoría son realizados en un solo centro y existen pocos estudios multicéntricos con una red de colaboración que entregue datos a nivel nacional como éste.…”